Skip to content
AnalystLens

Illumina 8-K Report, Regulation FD Disclosure (Mar 10, 2025)

Reports
Regulation FD·Exhibits & Filings
Filing Date
Filed March 10, 2025
Period End
March 10, 2025
Security
ILMN
In the record · 2016–202610-K1110-Q338-K167

ILMN filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 167 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Nov ’17Nov ’17
  2. Material agreement8-K · Sep ’20Sep ’20
  3. Leadership change8-K · Sep ’22Sep ’22
  4. Material agreement8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed March 10, 2025. Cited figures are marked; the original filing is the authoritative source.

Illumina, Inc. (Nasdaq: ILMN) filed this Form 8-K on March 10, 2025 under Item 7.01 (Regulation FD Disclosure), furnishing a press release that responds to a March 4, 2025 notice from the China Ministry of Commerce (MOFCOM) stating that Illumina is not permitted to export sequencing instruments into China.

The company said it respects MOFCOM's decision, will continue to comply with applicable laws, and continues to serve its clinical and research customers in China. Management reiterated its goal of high-single-digit revenue growth by 2027 while expanding margins. The company updated its fiscal 2025 guidance, now expecting Core Illumina non-GAAP diluted EPS of approximately $4.50a, and instituting an incremental cost reduction program of approximately $100 million for fiscal 2025.

The savings are intended to mitigate a range of potential scenarios for reduced revenue and operating income from the Greater China business, and include optimizing stock-based compensation and non-labor spending and accelerating certain productivity measures. The CFO stated the guidance provides for limited further earnings contribution from China and assumes a continuation of current macro trends.

The press release notes that the company cannot provide a GAAP reconciliation of its forward-looking non-GAAP guidance because certain items, such as acquisition-related expenses, restructuring activities, and the outcome of pending litigation, are difficult to predict. The forward-looking statements section also cites the MOFCOM "unreliable entities list" inclusion, tariffs, and litigation related to the GRAIL acquisition as risk factors.

02—Key points

Key Highlights

  1. Illumina says it is not permitted to export sequencing instruments into China following a March 4, 2025 MOFCOM notice, and that it is included on MOFCOM's "unreliable entities list" per the forward-looking statements section.
  2. Core Illumina fiscal 2025 non-GAAP diluted EPS guidance is approximately $4.50.
  3. The company is instituting an incremental cost reduction program of approximately $100 million for fiscal 2025.
  4. The cost reduction program includes optimizing stock-based compensation and non-labor spending and accelerating certain productivity measures.
  5. Management reiterated its target of high-single-digit revenue growth by 2027 and continued margin expansion, tied to the August 2024 Strategy Update.
  6. The guidance assumes limited further earnings contribution from China and a continuation of current macro trends, according to CFO Ankur Dhingra.
  7. The company provided no GAAP reconciliation for its forward-looking non-GAAP guidance, citing difficulty predicting items such as restructuring, acquisition-related expenses, and litigation outcomes.

03—Questions

Frequently Asked Questions

  1. Why did Illumina issue this announcement?

    Illumina issued a press release to respond to a March 4, 2025 notice from the China Ministry of Commerce that it is not permitted to export sequencing instruments into China, and to announce updated Core Illumina non-GAAP diluted EPS guidance for fiscal 2025 along with an incremental cost reduction program.

  2. What is the updated fiscal 2025 earnings guidance?

    Illumina expects Core Illumina fiscal 2025 non-GAAP diluted EPS of approximately $4.50.

  3. How much will the new cost reduction program save?

    The company is instituting an incremental cost reduction program of approximately $100 million for fiscal 2025, intended to mitigate the impact of potential reductions in revenue and operating income from its Greater China business.

  4. What does the company say about its China business going forward?

    Illumina states it has a long-standing presence in China and continues to serve its clinical and research customers there. The CFO said the new guidance provides for limited further earnings contribution from China.

  5. Does Illumina still expect long-term growth?

    Management said it remains focused on achieving high-single-digit revenue growth by 2027 while expanding margins, and will continue investing in its multiomics portfolio, services, data, and software offerings.

04—Continue

← View all 8-K filings